<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807455</url>
  </required_header>
  <id_info>
    <org_study_id>05DF1206</org_study_id>
    <nct_id>NCT01807455</nct_id>
  </id_info>
  <brief_title>An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine</brief_title>
  <official_title>An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of Restylane Vital&#xD;
      Lidocaine when acne scars are treated&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale</measure>
    <time_frame>36 weeks</time_frame>
    <description>Percentage of improved subjects at 36 weeks after first treatment session assessed using Subject GAIS. Scale range is Worse, No Change, Somewhat Improved, Much Improved and Very Much Improved. Alternatives Somewhat Improved to Very Much Improved are considered an improvement, i.e. a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Skin Quality and Overall Satisfaction Using a Subject Satisfaction Questionnaire</measure>
    <time_frame>36 weeks</time_frame>
    <description>Percentage of subjects satisfied with the overall appearance of the face at 36 weeks after first treatment session. Scale range is Very dissatisfied, Somewhat dissatisfied, Neither satisfied nor dissatisfied, Somewhat satisfied and Very satisfied. Alternatives Somewhat satisfied to Very satified are considered a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Acne Scarring Using the Scale for Acne Scar Severity (SCAR-S)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Percentage of subjects improved at 36 weeks after first treatment session assessed using SCAR-S. Scale range is Very severe, Severe, Moderate, Mild, Almost clear and Clear. The alternative Clear is considered the best outcome. Improvement is considered to be at least one step improvement on the scale toward the alternative Clear.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Local Tolerability After Treatment</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects reporting anticipated injection-related reactions after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Reporting During the Study</measure>
    <time_frame>36 weeks</time_frame>
    <description>Number of subjects reporting at least one adverse event (assessed as unrelated or related to treatment)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Restylane Vital Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Vital Lidocaine</intervention_name>
    <arm_group_label>Restylane Vital Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 25 to 45 years.&#xD;
&#xD;
          -  Caucasian with Fitzpatrick skin type I-III.&#xD;
&#xD;
          -  Must be cooperative and willing to comply with the instructions and procedures.&#xD;
&#xD;
          -  Provision of signed and dated informed consent to participate in the study.&#xD;
&#xD;
          -  Presence of depressed facial atrophic acne scars with a diameter of &lt;4 mm according to&#xD;
             at least SCAR-S score 3 category moderate (i.e. more than half of the face involved).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Icepick scarring or atrophic scars with a diameter of â‰¥4 mm covering more than 25% of&#xD;
             the face.&#xD;
&#xD;
          -  Active acne with inflammatory component.&#xD;
&#xD;
          -  Post-surgical scars in the face.&#xD;
&#xD;
          -  History of keloid formation or hypertrophic scars.&#xD;
&#xD;
          -  Use of isotretinoin within 12 months of the baseline visit.&#xD;
&#xD;
          -  Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide,&#xD;
             alpha-hydroxy acid at a concentration above 10% or beta-hydroxy acid at a&#xD;
             concentration above 2% or antibiotics within four months of the baseline visit.&#xD;
&#xD;
          -  Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation&#xD;
             (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or&#xD;
             vitamin E seven days before the injection, or a history of bleeding disorders.&#xD;
&#xD;
          -  Use of anti-inflammatory agents seven days before the injection.&#xD;
&#xD;
          -  History of radiation or skin tumours including actinic keratosis in the face.&#xD;
&#xD;
          -  Active skin disease, inflammation or related conditions, such as infection, perioral&#xD;
             dermatitis, seborrheic eczema and rosacea in the face.&#xD;
&#xD;
          -  History of or active collagen diseases or autoimmune diseases such as systemic lupus&#xD;
             erythematous, rheumatic arthritis, skin or systemic sclerosis.&#xD;
&#xD;
          -  Previous hypersensitivity to HA.&#xD;
&#xD;
          -  Previous hypersensitivity to lidocaine or other amide-type anaesthetics.&#xD;
&#xD;
          -  Concomitant treatment with chemotherapy, immunosuppressive agents, immunomodulatory&#xD;
             therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids&#xD;
             within 3 months of the baseline visit. (Inhaled corticoids are not an exclusion&#xD;
             criterion).&#xD;
&#xD;
          -  Presence of facial hair that may interfere with efficacy evaluations.&#xD;
&#xD;
          -  Previous tissue augmenting therapy or revitalization treatment in the treatment area&#xD;
             with HA or collagen, within 12 months of the baseline visit.&#xD;
&#xD;
          -  Permanent implant or treatment with fillers based on other material than HA or&#xD;
             collagen in the treatment area.&#xD;
&#xD;
          -  Laser, e.g. carbon dioxide and Fraxel, dermabrasion or facial light therapy, e.g. IPL,&#xD;
             in the treatment area within 12 months of the baseline visit.&#xD;
&#xD;
          -  Chemical peeling in the treatment area within 6 months of the baseline visit.&#xD;
&#xD;
          -  Previous surgery in the treatment area.&#xD;
&#xD;
          -  Nicotine use within 6 months before the baseline visit.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Participation in any other clinical study within 30 days before inclusion.&#xD;
&#xD;
          -  Any medical condition that in the opinion of the investigator makes the subject&#xD;
             unsuitable for inclusion (e.g. severe chronic disease, epilepsy, impaired cardiac&#xD;
             conduction, severely impaired hepatic function or severe renal dysfunction).&#xD;
&#xD;
          -  Other condition preventing the subject from entering the study in the investigator's&#xD;
             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects&#xD;
             anticipated to be unreliable or incapable of understanding the study assessment or&#xD;
             unrealistic expectations of treatment result.&#xD;
&#xD;
          -  Study staff or close relative of study staff (e.g. parents, children, siblings and&#xD;
             spouse).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Dierickx, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Skin and Laser Center</name>
      <address>
        <city>Boom</city>
        <zip>2850</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>November 9, 2015</results_first_submitted>
  <results_first_submitted_qc>December 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2016</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Restylane Vital Lidocaine</title>
          <description>Restylane Vital Lidocaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Restylane Vital Lidocaine</title>
          <description>Restylane Vital Lidocaine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="27" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale</title>
        <description>Percentage of improved subjects at 36 weeks after first treatment session assessed using Subject GAIS. Scale range is Worse, No Change, Somewhat Improved, Much Improved and Very Much Improved. Alternatives Somewhat Improved to Very Much Improved are considered an improvement, i.e. a better outcome.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Vital Lidocaine</title>
            <description>Restylane Vital Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale</title>
          <description>Percentage of improved subjects at 36 weeks after first treatment session assessed using Subject GAIS. Scale range is Worse, No Change, Somewhat Improved, Much Improved and Very Much Improved. Alternatives Somewhat Improved to Very Much Improved are considered an improvement, i.e. a better outcome.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Skin Quality and Overall Satisfaction Using a Subject Satisfaction Questionnaire</title>
        <description>Percentage of subjects satisfied with the overall appearance of the face at 36 weeks after first treatment session. Scale range is Very dissatisfied, Somewhat dissatisfied, Neither satisfied nor dissatisfied, Somewhat satisfied and Very satisfied. Alternatives Somewhat satisfied to Very satified are considered a better outcome.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Vital Lidocaine</title>
            <description>Restylane Vital Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Skin Quality and Overall Satisfaction Using a Subject Satisfaction Questionnaire</title>
          <description>Percentage of subjects satisfied with the overall appearance of the face at 36 weeks after first treatment session. Scale range is Very dissatisfied, Somewhat dissatisfied, Neither satisfied nor dissatisfied, Somewhat satisfied and Very satisfied. Alternatives Somewhat satisfied to Very satified are considered a better outcome.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Acne Scarring Using the Scale for Acne Scar Severity (SCAR-S)</title>
        <description>Percentage of subjects improved at 36 weeks after first treatment session assessed using SCAR-S. Scale range is Very severe, Severe, Moderate, Mild, Almost clear and Clear. The alternative Clear is considered the best outcome. Improvement is considered to be at least one step improvement on the scale toward the alternative Clear.</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Vital Lidocaine</title>
            <description>Restylane Vital Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Acne Scarring Using the Scale for Acne Scar Severity (SCAR-S)</title>
          <description>Percentage of subjects improved at 36 weeks after first treatment session assessed using SCAR-S. Scale range is Very severe, Severe, Moderate, Mild, Almost clear and Clear. The alternative Clear is considered the best outcome. Improvement is considered to be at least one step improvement on the scale toward the alternative Clear.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Local Tolerability After Treatment</title>
        <description>Number of subjects reporting anticipated injection-related reactions after treatment</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Vital Lidocaine</title>
            <description>Restylane Vital Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Local Tolerability After Treatment</title>
          <description>Number of subjects reporting anticipated injection-related reactions after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Reporting During the Study</title>
        <description>Number of subjects reporting at least one adverse event (assessed as unrelated or related to treatment)</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Vital Lidocaine</title>
            <description>Restylane Vital Lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Reporting During the Study</title>
          <description>Number of subjects reporting at least one adverse event (assessed as unrelated or related to treatment)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected by open questioning, information obtained from signs and symptoms detected during examination, observed by study personnel or spontaneous reports from the subjects.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Restylane Vital Lidocaine</title>
          <description>Restylane Vital Lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site nodule</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Implant site swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Q-Med AB</organization>
      <phone>+ 46 (0) 18 474 90 00</phone>
      <email>Reception.SEUPP@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

